FDA Accepts Curi Bio’s Letter of Intent into ISTAND Program to Qualify 3D Neuromuscular Junction Assay as a Non-Animal Replacement for Botulinum Toxin Potency Testing

The FDA accepted Curi Bio into its ISTAND program to pursue qualification of a 3D neuromuscular junction assay as a non-animal alternative for botulinum toxin potency testing. The regulatory engagement could support broader adoption of Curi Bio's assay platform and reduce reliance on animal-based testing, though no financial impact or commercialization timeline was disclosed.